Type of leukemia-Chronic Myeloid Leukemia (CML) Posts on Medivizor
Navigation Menu

Type of leukemia-Chronic Myeloid Leukemia (CML) Posts on Medivizor

Evaluating antithymocyte globulin in preventing graft-versus-host-disease after matched sibling donor transplantation

Evaluating antithymocyte globulin in preventing graft-versus-host-disease after matched sibling donor transplantation

Posted by on Aug 16, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the role of antithymocyte globulin in preventing graft-versus-host disease after matched sibling donor transplantation.  This study concluded that this treatment can reduce the occurrence of graft-versus-host-disease in these patients.   Some background One...

Read More

Impact of graft cryopreservation on allogeneic hematopoietic stem cell transplant outcomes using post-transplant cyclophosphamide

Impact of graft cryopreservation on allogeneic hematopoietic stem cell transplant outcomes using post-transplant cyclophosphamide

Posted by on Jun 21, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to compare outcomes of allogeneic hematopoietic stem cell transplant (alloHSCT) using cryopreserved (frozen) and fresh grafts in patients with blood cancers who received post-transplant cyclophosphamide (Cytoxan). This study concluded that cryopreservation (CP) does not affect the outcomes of HSCT in these patients....

Read More

Managing patients with chronic myeloid leukemia who fail responding to second generation tyrosine kinase inhibitors

Managing patients with chronic myeloid leukemia who fail responding to second generation tyrosine kinase inhibitors

Posted by on Jun 7, 2020 in Leukemia | 0 comments

In a nutshell The report recommends how to manage patients with chronic-phase chronic myeloid leukemia (CP-CML) who failed to respond to 2nd generation tyrosine kinase inhibitors (TKIs). The authors suggested to consider patient-specific factors and personalize treatment for such patients. Some background TKIs deactivate cancerous enzymes which cause...

Read More

Switching from frontline second-generation tyrosine kinase inhibitor treatment in chronic myeloid leukemia

Switching from frontline second-generation tyrosine kinase inhibitor treatment in chronic myeloid leukemia

Posted by on May 24, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate second treatments in patients with chronic myeloid leukemia (CML) who had been initially treated with second-generation tyrosine kinase inhibitors (TKI).  This study concluded that switching from second-generation TKIs in these patients was relatively uncommon.   Some background...

Read More

Kidney function in patients with chronic myeloid leukemia after stopping tyrosine kinase inhibitors

Kidney function in patients with chronic myeloid leukemia after stopping tyrosine kinase inhibitors

Posted by on May 17, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate kidney function in patients with chronic-phase (CP) chronic myeloid leukemia (CML) before and after tyrosine kinase inhibitor (TKI) treatment.  This study concluded that long-term TKI treatment leads to kidney side effects in these patients that may be irreversible after stopping...

Read More

The effect of stomach acid suppressants on the safety and effectiveness of dasatinib in patients with chronic myeloid leukemia

Posted by on Apr 21, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the influence of stomach acid suppressants on dasatinib treatment in patients with chronic-phase chronic myeloid leukemia.   This study concluded that these drugs did not influence dasatinib treatment in this patient group.   Some background...

Read More

The effects of hydroxychloroquine and imatinib on treatment outcomes in patients with chronic myeloid leukemia

Posted by on Apr 12, 2020 in Leukemia | 0 comments

In a nutshell The study evaluated the combined effects of imatinib (IM; Gleevec) and hydroxychloroquine (HCQ; Plaquenil) in patients with chronic-phase chronic myeloid leukemia (CP-CML) and residual leukemic stem cells. The authors found that this combination safely and moderately improved treatment outcomes in such patients compared to IM alone. Some...

Read More

Evaluating a method to predict the outcomes of patients with chronic myeloid leukemia treated with imatinib

Posted by on Mar 28, 2020 in Leukemia | 0 comments

In a nutshell The study tested whether the EUTOS long-term survival (ELTS) score is efficient to evaluate treatment response in patients with chronic myeloid leukemia (CML), treated with imatinib (Gleevec). The main finding was that ELTS could effectively predict treatment outcomes among such patients in the real world. Some background Initial...

Read More

Treating chronic myeloid leukemia with dasatinib

Posted by on Mar 13, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the long-term outcomes of dasatinib treatment for patients with chronic myeloid leukemia.   This study concluded that dasatinib is safe and provides positive long-term outcomes for these patients.   Some background Dasatinib (Sprycel) is a targeted therapy...

Read More